EHA 2022 | Chemotherapy and alloHSCT in the treatment of ALL
Irene Urbino
• 12 Jun 2022
Irene Urbino, MD, Città della Salute e della Scienza di Torino, Turin, Italy discusses the importance of chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of patients with acute lymphoblastic leukemia (ALL). With the availability of novel drugs, Dr Urbino describes the need to better understand these strategies and to consider when it is optimal to use only one strategy during treatment and when it is preferable to sequence these strategies, which is dependent on various factors such as the patient’s measurable residual disease (MRD) level and the toxicity of alloHSCT. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
